Literature DB >> 29395276

HLA-C1 ligands are associated with increased susceptibility to systemic lupus erythematosus.

Caterina Maria Gambino1, Danilo Di Bona2, Anna Aiello1, Ciriaco Carru3, Giovanni Duro4, Giuliana Guggino5, Angelo Ferrante5, Angelo Zinellu3, Calogero Caruso6, Giuseppina Candore7, Giulia Accardi1.   

Abstract

Recently, the role of killer cell immunoglobulin-like receptor (KIR) in autoimmune diseases has received increasing attention. The present study was undertaken to determine the association of KIR genes and the human leukocytes antigen (HLA) ligands with Systemic Lupus Erythematosus (SLE) and accompanying oxidative stress. Presence or absence of 17 KIR and 5 HLA loci was performed using the polymerase chain reaction-sequence specific primer (PCR-SSP) method by case-control study. A total of 45 SLE patients, and 60 healthy controls, all of Sicilian descent, were enrolled. Plasma values of the anti-oxidant molecule Taurine were determined in all subjects by capillary electrophoresis UV detection. The carrier frequency of the KIR2DS2 gene was significantly increased in SLE patients compared to healthy controls (73.3 versus 45.0%; OR = 3.36; 95% CI = 1.46-7.74; p = .005) suggesting a role of KIR2DS2 gene in the susceptibility to disease. We also observed a strong positive association between the presence of HLA-C1 ligands group and the disease (82.2% in SLE patients versus 41.7% in controls; OR = 6.47, 95% CI = 2.58-16.26; p < .0001). Stepwise logistic regression analysis supported the effect of the HLA-C1 ligands in SLE patients (OR = 7.06, 95% CI = 0.07-2.19; p = .002), while the KIR genes were no longer significant. Interestingly, we found that SLE patients HLA-C1 positive showed significantly decreased plasma levels of antioxidant activity marker Taurine (69.38 ± 28.49 μmol/L) compared to SLE patients HLA-C1 negative (108.37 ± 86.09 μmol/L) (p = .03). In conclusion, HLA-C1 ligands group was significantly associated with an increased risk of SLE as well as an increased oxidative stress status overall in SLE patients.
Copyright © 2018 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA; KIR; NK; SLE

Mesh:

Substances:

Year:  2018        PMID: 29395276     DOI: 10.1016/j.humimm.2018.01.005

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  6 in total

1.  Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.

Authors:  Filip Segerberg; Christian Lundtoft; Sarah Reid; Karin Hjorton; Dag Leonard; Gunnel Nordmark; Mattias Carlsten; Niklas Hagberg
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

Review 2.  HLA-C: An Accomplice in Rheumatic Diseases.

Authors:  Ruby J Siegel; S Louis Bridges; Salahuddin Ahmed
Journal:  ACR Open Rheumatol       Date:  2019-09-06

3.  Transcription Factor Activity Inference in Systemic Lupus Erythematosus.

Authors:  Raul Lopez-Dominguez; Daniel Toro-Dominguez; Jordi Martorell-Marugan; Adrian Garcia-Moreno; Christian H Holland; Julio Saez-Rodriguez; Daniel Goldman; Michelle A Petri; Marta E Alarcon-Riquelme; Pedro Carmona-Saez
Journal:  Life (Basel)       Date:  2021-04-01

Review 4.  Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Carly J Amato-Menker; Hajar El Hilali; Senthamil R Selvan; Edward J Filippone
Journal:  Antibodies (Basel)       Date:  2022-09-08

5.  Taurine promotes the production of CD4+CD25+FOXP3+ Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model.

Authors:  Jing Zhou; Yi Lu; Wei Wu; Yunhai Feng
Journal:  Allergy Asthma Clin Immunol       Date:  2021-06-19       Impact factor: 3.406

Review 6.  The Immunogenetic Conundrum of Preeclampsia.

Authors:  A Inkeri Lokki; Jenni K Heikkinen-Eloranta; Hannele Laivuori
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.